AMBER SURVANT: Open Payments
NPI 1407371289 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,328 in 75 payments from 11 companies in 2025. Trend: 2023 $858 · 2024 $840 · 2025 $1,328
Food & beverage: $1,228Education: $100
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $603 |
| ABBVIE INC. | 14 | $186 |
| Teva Pharmaceuticals USA, Inc. | 6 | $171 |
| Noven Therapeutics, LLC | 8 | $146 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Neurocrine BioSciences, Inc. | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
Products named: CAPLYTA, VRAYLAR, Xelstrym, AUSTEDO XR, REXULTI, INGREZZA, LYBALVI, HETLIOZ.
Industry payments across KY — which companies pay providers there.
